本帖最后由 老马 于 2012-1-13 21:20 编辑 $ f3 E& K c( b, f
, T9 m( ^. s4 C# J c" j爱必妥和阿瓦斯丁的比较- X- k" {, ?- ?( ?7 e, C3 i) R; R. F
) f4 \, \+ s" V* j' K
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ G- h5 f/ i& f% ?; {
% A) @% j! g% ?9 \: m) H) I
% I. w. k) h9 R( E: |# K5 ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 q6 R0 A1 R' S: L0 x) }==================================================
/ l1 c# x: N8 ], @6 _4 f0 ?; VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 q6 D+ |; K& xPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: c. @" H# t# u$ G4 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. F/ _. x+ S2 ^% L7 _
|